Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial.

Li, Yang; Zhang, Lei; Lv, Shuzheng; Wang, Xiaozeng; Zhang, Jian; Tian, Xiaoxiang; Zhang, Yan; Chen, Bojun; Liu, Dayue; Yang, Jie; Dong, Peikang; Xu, Yunzhong; Song, Yingmin; Shi, Junling; Li, Lian; Wang, Xuechang; Han, Yaling

Background: To assess the efficacy and safety of oral Guanxinshutong (GXST) capsules in Chinese patients with stable angina pectoris (SAP) in a prospective, multicenter, double-Blind, placebo-controlled, randomized clinical trial (clinicaltrials.gov Identifier: NCT02280850). Methods: Eligible patients were randomized 1:1 to the GXST or placebo group. Current standard antianginal treatment except for nitrate drugs was continued in both groups, who received an additional 4-week treatment of GXST capsule or placebo. Primary endpoint was the change from baseline in angina attack frequency after the 4-week treatment. Secondary endpoints included the reduction of nitroglycerin dose, score of Seatntle Agina Questionnaire, exercise tolerance test defined as time to onset of chest pain and ST-segment depression at least 1 mm greater than the resting one. Results: A total of 300 SAP patients from 12 centers in China were enrolled between January 2013 and October 2015, and they were randomly divided into the GXST group and the placebo group (150 patients in each group). Of whom, 287 patients completed the study (143 patients in the GXST group, 144 patients in the placebo group). The baseline characteristics of the two groups were comparable. After 4-week treatment with GXST capsules, the number of angina attacks and the consumption of short-acting nitrates were significantly reduced. In addition, the quality of life of patients were also substantially improved in the GXST group. No significant differences in the time of onset of angina and 1-mm ST segment depression were noted between the two groups. 7 patients (4.1%) in the GXST group and 3 patients (2.1%) in the placebo group reported at least one adverse event, respectively. Conclusions: GXST capsules are beneficial for the treatment of SAP patients.

CHINA; DRUG therapy for angina pectoris; CHEST pain diagnosis; DIAGNOSIS of mental depression; AGE factors in disease; ANGINA pectoris; PHARMACEUTICAL encapsulation; EXERCISE tests; HERBAL medicine; LONGITUDINAL method; MEDICAL cooperation; CHINESE medicine; NITROGLYCERIN; QUALITY of life; QUESTIONNAIRES; RESEARCH; RANDOMIZED controlled trials; TREATMENT effectiveness; BLIND experiment; DRUG administration; DRUG dosage; THERAPEUTICS

BMC Complementary & Alternative Medicine, 2019, Vol 19, Issue 1, p1

1472-6882

Academic Journal

10.1186/s12906-019-2778-z